Want to see HK:6160 full AI Analyst Report?
Top Page
BeOne Medicines Ltd
(6160)
Select Model
Select Model
Rating:66Neutral
Price Target:
HK$227.00
â–˛(0.44% Upside)
Action:Reiterated
Date:08/09/26
The score is driven primarily by improving financial performance (return to profitability, very strong gross margins, and solid free-cash-flow generation) and supportive technical momentum (price above key moving averages with positive MACD). These positives are meaningfully offset by stretched valuation (high P/E) and the need to prove durability of the turnaround given slower recent revenue growth and prior years of weak cash-flow consistency.
Positive Factors
Profitability and margins
The return to profitability, combined with consistently very high gross margins, indicates stronger earnings economics and meaningful product value. If maintained, this margin structure can support reinvestment in oncology research, commercialization, and expansion while improving resilience over the next several quarters.
Negative Factors
Slowing revenue growth
Revenue growth has decelerated despite the return to profitability, making future earnings expansion more dependent on execution, new indications, and sustained product uptake. Slower top-line growth can limit operating leverage and makes it harder for the company to compound results at its historical pace.
Read all positive and negative factors
Positive Factors
Negative Factors
Profitability and margins
The return to profitability, combined with consistently very high gross margins, indicates stronger earnings economics and meaningful product value. If maintained, this margin structure can support reinvestment in oncology research, commercialization, and expansion while improving resilience over the next several quarters.
Read all positive factors
BeOne Medicines Ltd (6160) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$306.22B
Dividend YieldN/A
Average Volume (3M)4.36M
Price to Earnings (P/E)57.8
Beta (1Y)0.88
Revenue Growth34.73%
EPS GrowthN/A
CountryHK
Employees12,000
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.45
Shares Outstanding1,427,230,000
10 Day Avg. Volume3,337,666
30 Day Avg. Volume4,360,447
Financial Highlights & Ratios
PEG Ratio-0.81
Price to Book (P/B)7.49
Price to Sales (P/S)6.10
P/FCF Ratio34.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$272.93Price Target Upside20.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)4.49
Revenue Forecast (FY)HK$52.95B
BeOne Medicines Ltd Business Overview & Revenue Model
Company Description
BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and so...
How the Company Makes Money
null...
BeOne Medicines Ltd Earnings Call Summary
Earnings Call Date:Aug 28, 2025
(Q2-2025)
| % Change Since: |
Next Earnings Date:Nov 05, 2026
Earnings Call Sentiment Positive
The earnings call reflects a strong performance by BeOne, with significant revenue growth driven by BRUKINSA's market leadership and robust R&D advancements. However, challenges remain due to aggressive competition and potential regulatory impacts. Overall, the positive aspects significantly outweigh the challenges.Positive Updates
Significant Revenue Growth
BeOne's revenue reached $1.3 billion, representing a 42% year-on-year growth.
Negative Updates
Competition and Pricing Challenges
Despite strong market position, competition aggressively discounting in the BTK market.
Read all updates
Q2-2025 Updates
Positive
Negative
Significant Revenue Growth
BeOne's revenue reached $1.3 billion, representing a 42% year-on-year growth.
Read all positive updates
Company Guidance
During the Q2 2025 earnings call for BeOne Medicines, the company provided strong financial guidance and updates on their strategic priorities. The company reported a revenue of $1.3 billion for the second quarter, marking a 42% year-over-year increase. BRUKINSA, the leading BTK inhibitor in the U.S. market, contributed $950 million to the global revenue, showcasing a 49% year-over-year growth. The company's gross margin improved to approximately 87%, attributed to favorable product mix and production cost efficiencies. The financial guidance for the full fiscal year 2025 was updated, with total revenue expectations ranging between $5 billion and $5.3 billion. The operating expenses are projected to remain between $4.1 billion and $4.4 billion, with a commitment to achieving positive GAAP operating income and generating positive free cash flow. The company also highlighted several upcoming R&D milestones, including global filings and pivotal data readouts for their key pipeline assets. Overall, BeOne Medicines emphasized their robust execution, strong market positioning, and continued focus on innovation and growth across their oncology portfolio.BeOne Medicines Ltd Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
66
Positive
Cash Flow
74
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.12B | 5.35B | 3.81B | 2.46B | 1.42B | 1.18B |
| Gross Profit | 5.38B | 4.56B | 3.22B | 2.08B | -511.06M | -447.86M |
| EBITDA | 1.10B | 589.69M | -396.44M | -1.12B | -1.72B | -1.39B |
| Net Income | 654.97M | 287.36M | -644.79M | -881.71M | -2.00B | -1.46B |
Balance Sheet | ||||||
| Total Assets | 9.18B | 8.23B | 5.92B | 5.81B | 6.38B | 8.65B |
| Cash, Cash Equivalents and Short-Term Investments | 5.10B | 4.59B | 2.63B | 3.17B | 4.53B | 6.62B |
| Total Debt | 1.14B | 1.09B | 1.08B | 930.18M | 596.67M | 694.64M |
| Total Liabilities | 4.00B | 3.84B | 2.59B | 2.27B | 2.00B | 2.40B |
| Stockholders Equity | 5.17B | 4.36B | 3.33B | 3.54B | 4.38B | 6.24B |
Cash Flow | ||||||
| Free Cash Flow | 1.31B | 943.13M | -669.77M | -1.75B | -1.97B | -1.61B |
| Operating Cash Flow | 1.49B | 1.13B | -140.63M | -1.16B | -1.50B | -1.30B |
| Investing Cash Flow | -182.66M | -276.56M | -548.35M | 60.00M | 1.08B | 640.66M |
| Financing Cash Flow | 1.12B | 1.06B | 193.45M | 416.48M | -18.97M | 3.64B |
BeOne Medicines Ltd Technical Analysis
Positive
226.00
Price Trends
204.83
Positive
189.66
Positive
191.48
Positive
Market Momentum
1.71
Positive
43.66
Neutral
12.44
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6160, the sentiment is Positive. The current price of 226 is above the 20-day moving average (MA) of 218.96, above the 50-day MA of 204.83, and above the 200-day MA of 191.48, indicating a neutral trend. The MACD of 1.71 indicates Positive momentum. The RSI at 43.66 is Neutral, neither overbought nor oversold. The STOCH value of 12.44 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:6160.
BeOne Medicines Ltd Risk Analysis
BeOne Medicines Ltd disclosed 93 risk factors in its most recent earnings report. BeOne Medicines Ltd reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
BeOne Medicines Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | HK$62.61B | 11.04 | 128.12% | ― | 305.94% | ― | |
70 Outperform | HK$164.53B | 112.83 | 6.06% | ― | 42.64% | 9.67% | |
66 Neutral | HK$306.22B | 57.80 | 14.22% | ― | 34.73% | ― | |
64 Neutral | HK$35.17B | 33.83 | 20.41% | ― | 32.63% | 8.87% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | HK$32.77B | -72.62 | -7.32% | ― | 34.83% | 58.94% | |
45 Neutral | HK$86.22B | -74.13 | -10.86% | ― | 42.47% | -15.80% |
* Healthcare Sector Average
HK:6160
BeOne Medicines Ltd
206.20
7.30
3.67%
HK:1801
Innovent Biologics
93.55
-4.30
-4.39%
HK:9926
Akeso, Inc.
90.30
-45.20
-33.36%
HK:9995
RemeGen Co. Ltd. Class H
73.75
-35.65
-32.59%
HK:1877
Shanghai Junshi Biosciences Co., Ltd. Class H
16.60
-17.14
-50.80%
HK:2696
Shanghai Henlius Biotech, Inc. Class H
63.00
-16.50
-20.75%
BeOne Medicines Ltd Corporate Events
BeOne Medicines Grants RSUs to 235 Employees Under Incentive Plan
Sep 4, 2026
BeOne Medicines Ltd. has granted 28,949 restricted share units, equivalent to 376,337 underlying shares or about 0.02% of its issued share capital, to 235 employees under its 2016 Share Option and Incentive Plan. The RSUs will vest over four years...
BeOne Medicines’ Interim Profit Soars on Double-Digit Revenue Growth
Aug 26, 2026
BeOne Medicines reported a strong interim performance for the six months ended June 30, 2026, with total revenues climbing 32.3% year-on-year to US$3.22 billion, driven mainly by a 31.4% increase in product revenue to US$3.17 billion. Despite a 14...
BeOne Medicines Sets Audit Committee Review for Dual-Market Interim Results
Aug 14, 2026
BeOne Medicines Ltd, a Swiss-incorporated biopharmaceutical company listed on the Hong Kong Stock Exchange, focuses on developing medicines for international markets and maintains dual financial reporting in the U.S. and Hong Kong. Its board, led ...
BeOne Medicines Grants New RSUs to Staff and Service Provider Under Incentive Plan
Aug 13, 2026
BeOne Medicines Ltd, a Swiss-incorporated biopharmaceutical company listed on the Hong Kong Stock Exchange, develops medicines in its core therapeutic areas and supplements its commercial strategy with unbranded disease awareness initiatives. The ...
BeOne Medicines Files Latest U.S. Form 10-Q, Highlights Global Shareholder Base
Aug 5, 2026
BeOne Medicines Ltd., a Swiss-incorporated drug developer with listings in Hong Kong, Shanghai and on Nasdaq via ADSs, has confirmed that it remains a large accelerated filer under U.S. securities rules and is not classified as an emerging growth ...
BeOne Medicines Posts Unaudited Q2 2026 Results and Cautions on Preliminary Guidance
Aug 5, 2026
BeOne Medicines Ltd, a Switzerland-incorporated oncology-focused biopharmaceutical group listed in Hong Kong, has reported unaudited condensed consolidated financial results for the three and six months ended June 30, 2026, prepared under U.S. GAA...
BeOne Medicines Issues New Shares to Fund Employee Stock Purchase Plan
Jul 30, 2026
BeOne Medicines has approved the issuance of 866,073 new shares to its wholly owned subsidiary BGNC2, to be re-transferred and held for the benefit of approximately 4,694 eligible employees participating in its 2018 Employee Stock Purchase Plan. T...
BeOne Medicines Sets August Timetable for Q2 and Interim 2026 Results
Jul 17, 2026
BeOne Medicines Ltd said it will publish its unaudited second-quarter 2026 financial results, prepared under U.S. GAAP and SEC rules, after Hong Kong trading hours on August 5, 2026, following review and approval by its audit committee. Management...
BeOne Medicines Grants New RSUs to 215 Employees Under 2016 Incentive Plan
Jul 8, 2026
BeOne Medicines Ltd has granted 33,388 restricted share units in the form of ADSs to 215 employees under its 2016 Share Option and Incentive Plan, representing 434,044 underlying shares or about 0.03% of its issued share capital. The awards carry ...
BeOne Medicines’ BRUKINSA Delivers Pivotal Phase 3 Win in Frontline Mantle Cell Lymphoma
Jun 30, 2026
BeOne Medicines reported positive topline Phase 3 results from its global MANGROVE trial, which tested BTK inhibitor BRUKINSA plus rituximab against standard bendamustine plus rituximab in previously untreated mantle cell lymphoma. The study met i...
BeOne Medicines Faces RMB446 Million Tax Payment in China, Sees No Material Impact
Jun 26, 2026
BeOne Medicines Ltd.’s wholly owned Chinese subsidiary has agreed with local tax authorities to adjust previously filed tax returns, resulting in an upcoming income tax and surcharge payment of about RMB446 million. The company stated that t...
BeOne Medicines Grants New Equity Awards Under 2016 Incentive Plan
Jun 18, 2026
BeOne Medicines has granted new equity awards under its 2016 Share Option and Incentive Plan, issuing options over 94,068 American depositary shares to six grantees, including two directors. The company also granted 1,499,134 restricted share unit...
BeOne Medicines Files U.S. Form S-8 to Expand Equity Incentive Plans
Jun 11, 2026
BeOne Medicines Ltd., a Swiss-incorporated biopharmaceutical company listed in Hong Kong, has filed a Form S-8 registration statement with the U.S. Securities and Exchange Commission. The filing covers shares issuable under its Fifth Amended and R...
BeOne Medicines Shareholders Approve All AGM Resolutions and Refresh Board
Jun 11, 2026
BeOne Medicines Ltd reported that all resolutions proposed at its 2026 annual general meeting were duly passed by shareholders, including approval of the audited 2025 Swiss statutory standalone and consolidated financial statements and the appropr...
BeOne Medicines Sets Out Board and Committee Structure to Bolster Governance
Jun 11, 2026
BeOne Medicines has detailed the composition of its board of directors and the allocation of responsibilities across five key board committees, underscoring a robust corporate governance framework. The company has appointed Chairman and CEO John V...
BeOne Medicines Secures Multiple HKEX Rule Waivers to Support Flexible Financing and Partnerships
Jun 11, 2026
BeOne Medicines has published an updated company information sheet dated 11 June 2026 outlining a series of waivers and exemptions it has obtained from strict compliance with various Hong Kong Stock Exchange Listing Rules and related ordinances. T...
BeOne Medicines Formalizes Compensation Committee Charter to Strengthen Governance
Jun 11, 2026
BeOne Medicines Ltd. has formalized the role and responsibilities of its Compensation Committee, which is tasked with overseeing compensation for directors and executive officers, as well as the company’s broader talent management and succes...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.